Lv Fang, Wu Xueying, Song Jin, Wang Pan, Ren Shucheng, Guo Wei, Xue Qi, Zhang Henghui, Zhao Jun
Department of Thoracic Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
Beijing Shijitan Hospital, Ninth School of Clinical Medicine, School of Oncology, Capital Medical University, Peking University, Capital Medical University, 100038, Beijing, China.
Biomark Res. 2021 Jun 2;9(1):41. doi: 10.1186/s40364-021-00287-8.
It has been suggested that the heterogeneity of TAAs in lung cancer may affect the therapeutic response and disease progression. Up to now, several tumor-associated antigen (TAA)-based cancer vaccines have been investigated in lung adenocarcinoma (LUAD); however, most of them have failed at the stage of clinical trials. The present study suggests that inter-tumoral heterogeneity of TAAs is large at single-cell resolution, while the communication between tumor cells and infiltrating T cells is closely related to the expression profile of TAAs.
有人提出，肺癌中肿瘤相关抗原（TAA）的异质性可能会影响治疗反应和疾病进展。到目前为止，已经在肺腺癌（LUAD）中研究了几种基于肿瘤相关抗原（TAA）的癌症疫苗；然而，它们中的大多数在临床试验阶段都失败了。本研究表明，在单细胞分辨率下，TAA的肿瘤间异质性很大，而肿瘤细胞与浸润性T细胞之间的通讯与TAA的表达谱密切相关。
